Eliane Schutte is Xeltis Chief Executive Officer since 2018. Under her leadership, the company expanded its strategy to cover vascular and valve applications, closed a €10.5 million  financing round in 2019, secured €15 million financing from the European Investment Bank and €15 million funding from the European Union in 2021 and Series D2 of €32 million funding in 2023. She initially joined Xeltis in 2015 as Chief Development Officer, leading its clinical trial program, product development strategy and regulatory. Eliane has extensive expertise in global product development and regulatory affairs in medical devices, with over 20 years of experience in the biotech industry. Prior to Xeltis, she was Vice President for global product development in peri-operative care at The Medicines Company. She was previously chief development officer at Profibrix, a Dutch-US biotech start-up acquired by The Medicines Company and vice president for regulatory affairs and EU operations at IsoTis Orthobiologics and started her carreer at Medtronic. Eliane was included in the list of The Top 50 Healthcare Technology CEOs by the Healthcare Technology Report in 2021 and 2022.